Sign in Subscribe
Cancer metastasis

Stereotactic Body Radiation Therapy Shows Promise for Metastatic Castration-Resistant Prostate Cancer

Strategic Insights

— 1 min read

Recent research from Centre Eugene Marquis in Rennes, France, has shed light on the effectiveness of stereotactic body radiation therapy (SBRT) in treating metastatic castration-resistant prostate cancer (CRPC). The study, published in Prostate Cancer and Prostatic Diseases, aimed to summarize evidence on SBRT in CRPC and found that it can significantly improve progression-free survival (PFS) in men with metachronous oligoprogression.

Key Takeaways:

  • The study included a systematic review of 19 articles on SBRT in CRPC, which were retrieved from a literature search on PubMed using specific keywords.
  • The review found that SBRT with androgen receptor pathway inhibitors significantly increased PFS, including biochemical progression-free survival, in a randomized phase II trial.
  • The level of evidence remains very low, and inclusion in prospective trials is the preferred option for this population of patients.
  • The study highlights the importance of further research in this area to better understand the potential benefits of SBRT in CRPC treatment.
  • The research was conducted by a team of experts from Centre Eugene Marquis, led by Jennifer Le Guevelou, and coordinated by Marie-Christine Roche, Radiation Therapy Department.

Statistics:

  • 108 articles were retrieved from the literature search on PubMed using the keywords "SBRT" AND "CRPC", and "stereotactic ablative radiotherapy (SABR)" AND "CRPC".
  • 19 articles were included in the systematic review, which focused on SBRT in CRPC.
  • The hazard ratio for PFS was 0.35 (p < 0.05) in a randomized phase II trial, indicating a significant improvement in PFS with SBRT and androgen receptor pathway inhibitors.

Sources:

  • Prostate Cancer and Prostatic Diseases. The current landscape of stereotactic body radiation therapy for metastatic castration-resistant prostate cancer. 2024.
  • Centre Eugene Marquis. Findings in Prostate Cancer (The current landscape of stereotactic body radiation therapy for metastatic castration-resistant prostate cancer). Chemicals & Chemistry. July 5, 2024; p 277.

Read more